Kezar Life Sciences Dirección
Dirección controles de criterios 2/4
El CEO de Kezar Life Sciences es Chris Kirk , nombrado en Nov 2023, tiene una permanencia de 9.75 años. compensación anual total es $2.60M, compuesta por 9.3% salario y 90.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.59% de las acciones de la empresa, por valor de $320.50K. La antigüedad media del equipo directivo y de la junta directiva es de 2 años y 7.5 años, respectivamente.
Información clave
Chris Kirk
Chief Executive Officer (CEO)
US$2.6m
Compensación total
| Porcentaje del salario del CEO | 9.3% |
| Permanencia del CEO | less than a year |
| Participación del CEO | 0.6% |
| Permanencia media de la dirección | 2yrs |
| Promedio de permanencia en la Junta Directiva | 7.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?
Dec 08
FDA clears Kezar Life Sciences' drug application for autoimmune hepatitis treatment
Oct 03Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?
Aug 15Kezar Life Sciences GAAP EPS of -$0.25 beats by $0.02
Aug 11Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case
Jul 27Kezar Life Sciences appoints Nick Mordwinkin as chief business officer
Jul 11We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate
Jan 03Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation
Aug 26We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate
Apr 05Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like
Mar 01Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings
Jan 25Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans
Dec 21
Kezar Life Sciences selected for the Nasdaq Biotechnology Index
Dec 14Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$96m |
| Jun 30 2024 | n/a | n/a | -US$99m |
| Mar 31 2024 | n/a | n/a | -US$101m |
| Dec 31 2023 | US$3m | US$242k | -US$102m |
| Sep 30 2023 | n/a | n/a | -US$88m |
| Jun 30 2023 | n/a | n/a | -US$83m |
| Mar 31 2023 | n/a | n/a | -US$74m |
| Dec 31 2022 | US$2m | US$468k | -US$68m |
| Sep 30 2022 | n/a | n/a | -US$64m |
| Jun 30 2022 | n/a | n/a | -US$61m |
| Mar 31 2022 | n/a | n/a | -US$58m |
| Dec 31 2021 | US$2m | US$443k | -US$55m |
| Sep 30 2021 | n/a | n/a | -US$51m |
| Jun 30 2021 | n/a | n/a | -US$48m |
| Mar 31 2021 | n/a | n/a | -US$45m |
| Dec 31 2020 | US$880k | US$426k | -US$42m |
| Sep 30 2020 | n/a | n/a | -US$40m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$37m |
| Dec 31 2019 | US$2m | US$410k | -US$35m |
| Sep 30 2019 | n/a | n/a | -US$31m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$26m |
| Dec 31 2018 | US$962k | US$365k | -US$23m |
| Sep 30 2018 | n/a | n/a | -US$20m |
| Jun 30 2018 | n/a | n/a | -US$16m |
| Mar 31 2018 | n/a | n/a | -US$11m |
| Dec 31 2017 | US$745k | US$325k | -US$9m |
Compensación vs. Mercado: La compensación total de Chris($USD2.60M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD647.72K).
Compensación vs. Ingresos: La compensación de Chris ha aumentado mientras la empresa no es rentable.
CEO
Chris Kirk (52 yo)
less than a year
Permanencia
US$2,602,155
Compensación
Dr. Christopher J. Kirk, also known as Chris, Ph.D. serves as Member of Scientific Advisory Board at Rain Oncology Inc. (formerly known as Rain Therapeutics Inc.) He is a Co-Founder of Kezar Life Sciences,...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | less than a year | US$2.60m | 0.59% $ 320.5k | |
| Co-Founder & Director | no data | US$4.83m | 0.60% $ 324.0k | |
| CFO & Secretary | 6.7yrs | US$2.01m | 0.026% $ 13.9k | |
| Co-Founder | no data | sin datos | sin datos | |
| Senior Vice President of Investor Relations & External Affairs | no data | sin datos | sin datos | |
| Chief Legal Officer | 5.6yrs | sin datos | 0.025% $ 13.4k | |
| Vice President of Human Resources | less than a year | sin datos | sin datos | |
| Senior Vice President of Research & Drug Discovery | 2.6yrs | sin datos | sin datos | |
| Senior Vice President of Clinical Development | 1.5yrs | sin datos | sin datos | |
| Senior VP & Corporate Controller | no data | sin datos | sin datos |
2.0yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de KZR se considera experimentado (2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 9.8yrs | US$2.60m | 0.59% $ 320.5k | |
| Co-Founder & Director | 9.8yrs | US$4.83m | 0.60% $ 324.0k | |
| Independent Director | 7.9yrs | US$155.34k | 0.087% $ 47.3k | |
| Independent Director | 8.8yrs | US$141.22k | 1.22% $ 661.8k | |
| Independent Chairman | 7.1yrs | US$194.56k | 0% $ 0 | |
| Independent Director | 4.9yrs | US$149.45k | 0% $ 0 | |
| Independent Director | 2.9yrs | US$164.59k | 0% $ 0 | |
| Independent Director | 3.4yrs | US$161.58k | 0% $ 0 |
7.5yrs
Permanencia media
54yo
Promedio de edad
Junta con experiencia: La junta directiva de KZR se considera experimentada (7.5 años de antigüedad promedio).